During the corresponding time, Meiragtx Holdings Plc recorded a revenue increase by 8608.59 % year on year, sequentially revenue grew by 109604.44 %. While revenue at the Meiragtx Holdings Plc's corporate clients
Meiragtx Holdings Plc's Comment on Sales, Marketing and Customers
The company focuses on patients with inherited retinal dystrophies caused by defects in the AIPL1 and RPE65 genes. Its market segments include individuals with inherited retinal dystrophy due to AIPL1 gene defects and those with RPE65-associated retinal dystrophy, such as Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP) related to RPE65 mutations. The estimated patient population comprises approximately 6,000 RPE65-deficiency patients across the United States, Japan, Germany, France, Spain, Italy, and the United Kingdom, with about 30% under age 30 and approximately 50 new cases diagnosed annually. The company has developed gene therapy candidates AAV-AIPL1 and AAV-RPE65, both of which have received orphan drug and rare pediatric disease designations from the FDA and the European Commission. The FDA has approved Luxturna, a gene therapy for RPE65-associated retinal dystrophy developed by Spark Therapeutics, Inc., which was acquired by Roche. The company aims to treat the central retina extensively to maintain structural integrity and preserve central vision in affected patients.
In an extraordinary breakthrough in the field of genetic medicine, MeiraGTx Holdings plc (Nasdaq: MGTX), a leading clinical-stage genetic medicines company, has announced the publication of a significant study in The Lancet that reports the efficacy of its gene therapy, rAAV8.hRKp.AIPL1, in treatin...
Meiragtx Holdings Plc’s Comment on Sales, Marketing and Customers
The company focuses on patients with inherited retinal dystrophies caused by defects in the AIPL1 and RPE65 genes. Its market segments include individuals with inherited retinal dystrophy due to AIPL1 gene defects and those with RPE65-associated retinal dystrophy, such as Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP) related to RPE65 mutations. The estimated patient population comprises approximately 6,000 RPE65-deficiency patients across the United States, Japan, Germany, France, Spain, Italy, and the United Kingdom, with about 30% under age 30 and approximately 50 new cases diagnosed annually. The company has developed gene therapy candidates AAV-AIPL1 and AAV-RPE65, both of which have received orphan drug and rare pediatric disease designations from the FDA and the European Commission. The FDA has approved Luxturna, a gene therapy for RPE65-associated retinal dystrophy developed by Spark Therapeutics, Inc., which was acquired by Roche. The company aims to treat the central retina extensively to maintain structural integrity and preserve central vision in affected patients.
Sources:
Meiragtx Holdings Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Meiragtx Holdings Plc’s corporate clients.
For your research, we’ve provided 9 tables on Meiragtx Holdings Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
3.7 %